2021
Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity
Martin DT, Lee JS, Liu Q, Galiana G, Sprenkle PC, Humphrey PA, Petrylak DP, Weinreb JC, Schulam PG, Weiss RM, Fahmy TM. Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. Nanomedicine Nanotechnology Biology And Medicine 2021, 40: 102477. PMID: 34740868, DOI: 10.1016/j.nano.2021.102477.Peer-Reviewed Original ResearchConceptsFunctionalized nanoparticlesProstate cancerTumor specificityNanoparticlesHuman prostate cancer biopsiesTumor-bearing mouse modelClaudin-3Average diameterLiver signal intensityProstate cancer biopsiesKey imaging toolContrast-enhanced MRIImaging specificityClostridium perfringens enterotoxinPotential clinical applicabilityDetection toolsMouse modelTumor localizationCancer biopsiesCancer specificityCldn-3Perfringens enterotoxinClinical applicabilityHigh expressionHigh gradeAchieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles
Li G, He S, Schätzlein AG, Weiss RM, Martin DT, Uchegbu IF. Achieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles. Journal Of Controlled Release 2021, 332: 210-224. PMID: 33607176, DOI: 10.1016/j.jconrel.2021.02.007.Peer-Reviewed Original Research
2019
Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target
Martin DT, Shen H, Steinbach-Rankins JM, Zhu X, Johnson KK, Syed J, Saltzman WM, Weiss RM. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target. Molecular Cancer Therapeutics 2019, 18: molcanther.1079.2017. PMID: 30381445, PMCID: PMC6363894, DOI: 10.1158/1535-7163.mct-17-1079.Peer-Reviewed Original ResearchConceptsBladder cancer cell linesBladder tumorsBladder cancerCancer cell linesHigh-grade bladder cancer cell linesCancer xenograft mouse modelBladder cancer growthAggressive bladder cancerPotential therapeutic targetHuman bladder tumorsXenograft mouse modelBladder cancer progressionCell linesBladder tumor cellsCurative potentialOptimal treatmentTumor gradePatient outcomesReduced cell migrationTumor volumeTumor categoryMouse modelTherapeutic targetTumor aggressivenessCancer growth
2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine Nanotechnology Biology And Medicine 2013, 9: 1124-1134. PMID: 23764660, PMCID: PMC3815967, DOI: 10.1016/j.nano.2013.05.017.Peer-Reviewed Original ResearchConceptsHistone deacetylase inhibitor belinostatBladder cancerBladder permeability barrierNon-invasive bladder cancerCultured bladder cancer cellsBladder cancer cellsChemotherapy efficacyIntravesical drug deliveryXenograft tumorsMouse bladderMouse modelConvincing dataHuman ureterBelinostatCancerCancer cellsLower IC50TumorsAcetyl-H4Tissue penetrationCLINICAL EDITORIntracellular uptakeDeliveryCellsPatients